Lil­ly in­vests $2.5B in new Ger­man site to boost tirzepatide sup­ply, $100M for lo­cal biotechs

Eli Lil­ly is set to build a new $2.5 bil­lion fa­cil­i­ty in Ger­many to in­crease man­u­fac­tur­ing ca­pac­i­ty for its block­buster di­a­betes and obe­si­ty drugs, and the phar­ma gi­ant al­so an­nounced Fri­day it will spend up to $100 mil­lion on lo­cal biotechs.

The fa­cil­i­ty will be lo­cat­ed in Alzey, which is about an hour dri­ve from Frank­furt. It’s ex­pect­ed to boost the com­pa­ny’s in­jectable pro­duc­tion as well as its de­vice man­u­fac­tur­ing ca­pa­bil­i­ties and, ul­ti­mate­ly, in­crease Lil­ly’s in­cretin sup­ply. Lil­ly’s block­buster drug tirzepatide — ap­proved as Moun­jaro for type 2 di­a­betes and Zep­bound for obe­si­ty — tar­gets GIP and GLP-1 re­cep­tors, which are nat­u­ral­ly ac­ti­vat­ed by in­cretin hor­mones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER